ストックスクリーナーアプリを入手
3.18
2.91%
0.09
アフターアワーズ：
3.19
0.010
+0.31%
前日終値:
$3.09
開ける：
$3.07
24時間の取引高:
314.17K
Relative Volume:
0.69
時価総額：
$229.97M
収益：
-
当期純損益:
$-113.28M
株価収益率:
-1.7136
EPS:
-1.8557
ネットキャッシュフロー:
$-105.55M
1週間 パフォーマンス:
+8.90%
1か月 パフォーマンス:
+41.96%
6か月 パフォーマンス:
-3.93%
1年 パフォーマンス:
+130.43%
1日の値動き範囲:
$3.03
$3.23
1週間の範囲:
$2.76
$3.23
52週間の値動き範囲:
$1.21
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
名前
Acumen Pharmaceuticals Inc
セクター
電話
617-344-4190
住所
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
3.18 | 230.69M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-07-26 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-20 | 再開されました | BofA Securities | Buy |
| 2023-05-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 開始されました | BTIG Research | Buy |
| 2022-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-07-26 | 開始されました | BofA Securities | Neutral |
| 2021-07-26 | 開始されました | Credit Suisse | Outperform |
| 2021-07-26 | 開始されました | Stifel | Buy |
| 2021-07-26 | 開始されました | UBS | Buy |
すべてを表示
Acumen Pharmaceuticals Inc (ABOS) 最新ニュース
An Alzheimer’s drug developer will join two live online events Sept. 9 and 10 - Stock Titan
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 - Barchart.com
Acumen Pharmaceuticals Earnings Call: Science vs. Runway - TipRanks
Acumen Pharmaceuticals Inc (ABOS) Stock News Today - TradingKey
Acumen Pharmaceuticals (ABOS) Advances 4.7% to $2.67 as Momentum BuildsForce Index - vinanet.vn
Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026 - TradingKey
Acumen Pharmaceuticals (ABOS) Edges Higher: Biotech Stock Gains 1.59% as Bulls Target $2.68 ResistanceCall Wall - vinanet.vn
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4 - moomoo.com
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Acumen Pharmaceuticals Q2 EPS $(0.45) misses $(0.34) estimate - scanx.trade
Acumen Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ABOS) 2026-08-12 - Seeking Alpha
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position supports pipeline - TradingView
Acumen Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position and pipeline progress - TradingView
Second quarter earnings and operational progress released by Acumen Pharmaceuticals, Inc. - Traders Union
Acumen Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals Reports Q2 Results, Advances Alzheimer’s Programs - TipRanks
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Reports Second-Quarter 2026 Results and Advances Alzheimer’s Pipeline, with ALTITUDE-AD Topline Data Expected in Late 2026 - Quiver Quantitative
Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates - TradingView
Acumen Reports Q2 Net Loss as Alzheimer’s Trial Readout Nears - Quiver Quantitative
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals, Inc. (ABOS) stock price, news, quote and history - Yahoo Finance Australia
Acumen Pharmaceuticals (ABOS.US) will release its earnings report before the market opens on August 12. - Moomoo
Acumen Pharmaceuticals (ABOS) Holds Ground at $2.25, Poised Between Key Support and ResistanceDiamond Pattern - vinanet.vn
Enterprise value to EBITDA forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 - manilatimes.net
Alzheimer’s drug developer Acumen sets Aug. 12 webcast at 8 a.m. - Stock Titan
Price to book forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals (ABOS) Holds Steady at $2.24 as Key Support and Resistance Levels Come Into FocusBPI Reversal - vinanet.vn
Acumen Pharmaceuticals (ABOS) Projected to Release Earnings on Tuesday - MarketBeat
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Acumen Pharmaceuticals Inc - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.235|Chg%:+0.105 - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.440|Chg%:+0.160 - TradingKey
Price to earnings forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Enterprise value to revenue forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals Inc (ABOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Institutional Confidence - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Income Statement - TradingKey
Acumen Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acumen Pharmaceuticals Inc. (ABOS) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Alzheimer's Candidate AdvancesEarnings Outlook Update - vinanet.vn
Acumen Pharmaceuticals (ABOS) Slips Slightly, Holds Above Key Support LevelLow Volatility Picks - vinanet.vn
Acumen Pharmaceuticals Inc. Q1 2026 Earnings: Narrowed Loss Beats Expectations, Stock SlipsSpecial Dividend Alert - dars.gov.et
Are medical stocks lagging Acumen Pharmaceuticals (ABOS) this year? - MSN
Acumen Pharmaceuticals Presents Enhanced Brain Delivery Program Data and Early Alzheimer?S Disease Insights At Alzheimer?S Association International Conference 2026 - marketscreener.com
Acumen Pharmaceuticals Inc (ABOS) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):